Knowledge base
1,274 claims across 14 domains
Every claim is an atomic argument with evidence, traceable to a source. Browse by domain or search semantically.
All 1,274ai alignment 325internet finance 263health 211space development 171entertainment 131grand strategy 101energy 23mechanisms 18collective intelligence 14robotics 5manufacturing 5critical systems 3unknown 3teleological economics 1
the healthcare cost curve bends up through 2035 because new curative and screening capabilities create more treatable conditions faster than prices decline
The fundamental tension in healthcare economics: medicine can now cure diseases that were previously only manageable, but the cures are expensive and the newly treatable population is enormous. The transition period through ~2035 sees rising costs as new therapies launch at premium prices and reach
the physician role shifts from information processor to relationship manager as AI automates documentation triage and evidence synthesis
PwC projects $1 trillion in annual US healthcare spending will shift from administrative overhead and brick-and-mortar infrastructure to AI-driven, digital-first models by 2035. The value creation ranks: (1) documentation automation (most certain -- $1.85B ambient market growing 28.7% annually), (2)
value based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk
As of the most recent HCP-LAN measurement, 59.5% of US healthcare payments are tied to value and quality in some form, while 40.5% remain pure fee-for-service. But the composition matters enormously: only 19.6% of payments are in risk-based arrangements, and just 14% flow through fully capitated mod
chronic condition special needs plans grew 71 percent in one year indicating explosive demand for disease management infrastructure
C-SNPs (Chronic Condition Special Needs Plans) grew 71% from 2024 to 2025, reaching 1.2 million enrollees and representing 16% of all Special Needs Plan enrollment. This is the fastest-growing segment of Medicare Advantage and signals a structural shift toward managed care models specifically design
medicare advantage crossed majority enrollment in 2023 marking structural transformation from supplement to dominant program
Medicare Advantage enrollment crossed the 50% threshold in 2023 (30.8M enrollees, 51% penetration) and reached 54% by 2025 (34.1M enrollees). This represents a structural inflection point where managed care became the default Medicare experience rather than an alternative. The trajectory is accelera
medicare advantage market is an oligopoly with unitedhealthgroup and humana controlling 46 percent despite nominal plan choice
The Medicare Advantage market exhibits classic oligopoly structure: UnitedHealthGroup (9.9M enrollees, 29%) and Humana (5.7M enrollees, 17%) together control 46% of all MA enrollment. This concentration exists despite beneficiaries having an average of 9 plan options, with 36% of beneficiaries havin
medicare advantage spending gap grew 47x while enrollment doubled indicating scale worsens overpayment problem
The federal spending gap between Medicare Advantage and fee-for-service Medicare grew from $18 billion in 2015 to $84 billion in 2025 — a 4.7x increase. During the same period, MA enrollment roughly doubled from ~16 million to 34 million beneficiaries. This means the overpayment problem is getting w
gatekeeping systems optimize primary care at the expense of specialty access creating structural bottlenecks
Healthcare systems that require primary care referrals for specialty access (gatekeeping) face a fundamental tradeoff: they improve primary care coordination and reduce inappropriate specialty utilization, but they concentrate demand at referral choke points that become capacity bottlenecks under re
nhs demonstrates universal coverage without adequate funding produces excellent primary care but catastrophic specialty access
The NHS provides the clearest evidence that universal coverage alone does not guarantee good health outcomes across all dimensions of care. Despite ranking **3rd overall** in the Commonwealth Fund's Mirror Mirror 2024 international comparison, the NHS simultaneously exhibits the worst specialty acce
acc 2025 distinguishes glp1 symptom improvement from mortality reduction in hfpef
The American College of Cardiology's first major statement on anti-obesity medications in heart failure explicitly states that 'insufficient evidence exists to confidently conclude that semaglutide and tirzepatide reduce HF events in individuals with HFpEF and obesity' despite acknowledging improvem
the mental health supply gap is widening not closing because demand outpaces workforce growth and technology primarily serves the already served rather than expanding access
The US behavioral health market was valued at $89-95 billion in 2024, projected to reach $165 billion by 2034. But the supply side cannot keep pace. SAMHSA projects a shortage of approximately 250,510 professionals across nine critical mental health occupations, with demand for behavioral health pra
Page 9 of 9